XML 51 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
United States and Foreign Components of Consolidated Loss Before Income Taxes

U.S and foreign components of consolidated loss before income taxes for the years ended December 31, 2024, 2023 and 2022, was as follows (in thousands):

 

 

 

2024

 

 

2023

 

 

2022

 

Loss before income taxes:

 

 

 

 

 

 

 

 

 

U.S.

 

$

(21,318

)

 

$

(38,281

)

 

$

(43,096

)

Foreign

 

 

562

 

 

 

959

 

 

 

759

 

 Loss before income taxes

 

$

(20,756

)

 

$

(37,322

)

 

$

(42,337

)

 

Provision Benefit for Income Taxes

The provision for income taxes for the years ended December 31, 2024, 2023 and 2022, was as follows (in thousands):

 

 

 

2024

 

 

2023

 

 

2022

 

Provision for income taxes:

 

 

 

 

 

 

 

 

 

Current:

 

 

 

 

 

 

 

 

 

Foreign

 

$

130

 

 

$

285

 

 

$

520

 

Federal

 

 

 

 

 

 

 

 

 

State

 

 

70

 

 

 

36

 

 

 

5

 

Total current

 

 

200

 

 

 

321

 

 

 

525

 

Deferred:

 

 

 

 

 

 

 

 

 

Foreign

 

 

 

 

 

 

 

 

 

Federal

 

 

3

 

 

 

2

 

 

 

(18

)

State

 

 

2

 

 

 

2

 

 

 

(19

)

Total deferred

 

 

5

 

 

 

4

 

 

 

(37

)

Provision for income taxes

 

$

205

 

 

$

325

 

 

$

488

 

 

 

 

 

 

 

 

 

 

 

 

Difference Between Provision for Income Taxes and Amounts Computed by Applying Federal Statutory Income Tax Rate to Loss before Taxes

The difference between the provision for income taxes and the amount computed by applying the federal statutory income tax rate to loss before taxes for the years ended December 31, 2024, 2023 and 2022, was as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

2024

 

 

2023

 

 

2022

 

Federal statutory tax

 

$

(4,359

)

 

$

(7,838

)

 

$

(8,891

)

Federal research credits

 

 

(853

)

 

 

(1,065

)

 

 

(1,874

)

State research credits

 

 

(767

)

 

 

(642

)

 

 

(822

)

Expiration of federal carryovers

 

 

5,206

 

 

 

7,284

 

 

 

4,858

 

Change in valuation allowance

 

 

(2,357

)

 

 

1,361

 

 

 

6,379

 

Compensation related items

 

 

4,015

 

 

 

3,257

 

 

 

1,794

 

State taxes

 

 

(259

)

 

 

(1,710

)

 

 

(1,127

)

Revision to prior year items

 

 

(676

)

 

 

(664

)

 

 

 

Other

 

 

255

 

 

 

342

 

 

 

171

 

Provision for income taxes

 

$

205

 

 

$

325

 

 

$

488

 

 

 

 

 

 

 

 

 

 

 

Significant Components of Deferred Tax Assets and Liabilities The significant components of the Company’s deferred tax assets and liabilities at December 31, 2024, 2023 and 2022, were as follows (in thousands):

 

 

December 31,

 

 

 

2024

 

 

2023

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

127,184

 

 

$

133,476

 

Research and development credit carryforwards

 

 

29,739

 

 

 

28,567

 

Capitalized research and development

 

 

35,861

 

 

 

33,571

 

Compensation related items

 

 

9,437

 

 

 

10,306

 

Operating leases

 

 

3,005

 

 

 

3,462

 

Other

 

 

10,928

 

 

 

9,823

 

Total deferred tax assets

 

 

216,154

 

 

 

219,205

 

Valuation allowance

 

 

(214,321

)

 

 

(216,888

)

Net deferred tax assets

 

$

1,833

 

 

$

2,317

 

 

 

 

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

 

Right-of-use assets

 

$

1,676

 

 

$

2,173

 

Other

 

 

226

 

 

 

209

 

Total deferred tax liabilities

 

$

1,902

 

 

$

2,382

 

 

The valuation allowance decreased by $2.6 million for the year ended December 31, 2024, compared to the increase of $1.0 million and $6.4 million for the years ended December 31, 2023 and 2022, respectively. The Company believes that, based on a number of factors, the available objective evidence creates sufficient uncertainty regarding the realizability of the deferred tax assets such that a valuation allowance has been recorded. These factors include the Company’s history of net losses since its inception, the need for regulatory approval of the Company’s products prior to commercialization and expected near-term future losses. The Company expects to maintain a valuation allowance until circumstances change.

Gross Amounts and Dates of Expiration of Tax Credits and Carryovers

 

 

 

 

 

Expires

 

 

Expires

 

 

Expires

 

 

No

 

 

 

Total

 

 

2025-2027

 

 

2028-2034

 

 

2035-2044

 

 

Expiration

 

Federal losses carryovers

 

$

559,551

 

 

$

58,345

 

 

$

193,684

 

 

$

116,604

 

 

$

190,918

 

California loss carryovers

 

 

108,685

 

 

 

 

 

 

67,796

 

 

 

40,889

 

 

 

 

Other state loss carryovers

 

 

45,090

 

 

 

128

 

 

 

2,762

 

 

 

30,630

 

 

 

11,570

 

Federal research credits

 

 

17,074

 

 

 

1,279

 

 

 

1,927

 

 

 

13,868

 

 

 

 

California research credits

 

 

16,011

 

 

 

 

 

 

 

 

 

 

 

 

16,011

 

Federal foreign tax credits

 

 

610

 

 

 

610

 

 

 

 

 

 

 

 

 

 

Reconciliation of Unrecognized Tax Benefits

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in thousands):

 

 

December 31,

 

 

December 31,

 

 

 

2024

 

 

2023

 

Unrecognized tax benefits at beginning of period

 

$

7,924

 

 

$

8,652

 

Decreases related to expired carryforwards

 

 

(344

)

 

 

(1,126

)

Decreases related to administrative proceedings

 

 

(127

)

 

 

 

Increases related to prior year tax positions

 

 

94

 

 

 

100

 

Increases related to current year tax positions

 

 

290

 

 

 

298

 

Unrecognized tax benefits at end of period

 

$

7,837

 

 

$

7,924

 

The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense.